GRASP65 Inhibitors
GRASP65 is crucial for maintaining the structural integrity of the Golgi apparatus, a central organelle in the secretory pathway of eukaryotic cells. The inhibitors mentioned primarily focus on disrupting Golgi function, microtubule dynamics, vesicle trafficking, and intracellular signaling pathways.Compounds like Brefeldin A, Golgicide A, and Tunicamycin directly target the Golgi apparatus, altering its structure and function. Brefeldin A, for instance, disrupts Golgi organization by inhibiting ARF proteins, which are essential for vesicle formation and trafficking. This disruption can indirectly affect GRASP65's role in maintaining Golgi structure. Similarly, Golgicide A and Tunicamycin impact Golgi dynamics, potentially influencing GRASP65 function.
Other inhibitors, such as Nocodazole, Cytochalasin D, and Dynasore, affect the cytoskeleton and vesicle trafficking. These processes are closely linked to Golgi organization and function. By disrupting microtubules or actin filaments, or inhibiting dynamin, these compounds can indirectly impact GRASP65.Additionally, compounds like Thapsigargin, Forskolin, Wortmannin, and Chloroquine modulate intracellular signaling and trafficking pathways. For example, Thapsigargin affects calcium homeostasis, while Forskolin alters cAMP levels, each influencing cellular processes that can indirectly affect GRASP65's role in Golgi organization.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A disrupts Golgi structure and function by inhibiting ADP-ribosylation factor (ARF), which indirectly affects GRASP65's role in Golgi stacking and maintenance. | ||||||
Golgicide A | 1005036-73-6 | sc-215103 sc-215103A | 5 mg 25 mg | $191.00 $683.00 | 11 | |
Golgicide A is a specific inhibitor of the Golgi BFA resistance factor 1 (GBF1), influencing Golgi apparatus dynamics and potentially impacting GRASP65 function. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $59.00 $85.00 $143.00 $247.00 | 38 | |
Nocodazole disrupts microtubules, affecting intracellular transport and indirectly influencing GRASP65 function in Golgi organization. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
Monensin is an ionophore that disrupts Golgi function by altering pH levels, which can indirectly influence GRASP65-mediated Golgi stacking. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Tunicamycin inhibits N-linked glycosylation, disrupting normal Golgi function, which may indirectly affect GRASP65's role in Golgi stacking. | ||||||
ALLM (Calpain Inhibitor) | 136632-32-1 | sc-201268 sc-201268A | 5 mg 25 mg | $143.00 $388.00 | 23 | |
Ilomastat, a matrix metalloproteinase inhibitor, can affect cellular trafficking and extracellular matrix remodeling, potentially influencing GRASP65 function. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin disrupts calcium homeostasis in the endoplasmic reticulum, indirectly affecting Golgi function and potentially GRASP65's role. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin elevates cAMP levels, influencing various signaling pathways that may indirectly affect GRASP65's function in Golgi organization. | ||||||